Case Report
Copyright ©2007 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 7, 2007; 13(45): 6115-6118
Published online Dec 7, 2007. doi: 10.3748/wjg.v13.i45.6115
Epidermal growth factor receptor antibody plus recombinant human endostatin in treatment of hepatic metastases after remnant gastric cancer resection
Long Sun, Huang-Yang Ye, Ying-Hong Zhang, Yong-Song Guan, Hua Wu
Long Sun, Hua Wu, Minnan PET Center, The First Hospital of Xiamen, Fujian Medical University, Xiamen 316003, Fujian Province, China
Huang-Yang Ye, Ying-Hong Zhang, Department of Oncology, The First Hospital of Xiamen, Fujian Medical University, Xiamen 316003, Fujian Province, China
Yong-Song Guan, State Key Laboratory of Biotherapy, West China Medical School, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: All authors contributed equally to the work.
Correspondence to: Hua Wu, Minnan PET Center, The First Hospital of Xiamen, Fujian Medical University, Xiamen 316003, Fujian Province, China. wuhua1025@163.com
Telephone: +86-592-2139527 Fax: +86-592-2139527
Received: July 31, 2007
Revised: September 5, 2007
Accepted: October 26, 2007
Published online: December 7, 2007
Abstract

We report a 55-year-old male who developed advanced hepatic metastasis and peritoneal carcinomatosis after resection of remnant gastric cancer resection 3 mo ago. The patient only received epidermal growth factor (EGF) receptor antibody (Cetuximab) plus recombinant human endostatin (Endostar). Anti-tumor activity was assessed by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computer tomography (PET/CT) at baseline and then every 4 wk. The case illustrates that 18FDG-PET/CT could make an early prediction of the response to Cetuximab plus Endostar in such clinical situations. 18FDG-PET/CT is a useful molecular imaging modality to evaluate the biological response advanced hepatic metastasis and peritoneal carcinomatosis to Cetuximab plus Endostar in patients after remnant gastric cancer resection.

Keywords: Hepatic metastasis, Remnant gastric cancer, Cetuximab, Recombinant human endostatin, 18F-fluorodeoxyglucose, Positron emission tomography/computer tomography